Revaluation of clopidogrel: let the data speak for themselves

Abstract

Clopidogrel was believed to be superior to aspirin by the well-known CAPRIE trial. However, no other large clinical trials demonstrated the same results, but all focused on the combination use of clopidogrel with aspirin, and combination therapy in CREDO was called the “Emperor’s New Clothes”. However, no one overturned the results of these clinical trials by quantitatively analyzing them. We reviewed ten large-scale clinical trials about clopidogrel. On the basis of results of CAPRIE, CREDO and CHARISMA trials, we re-estimated their minimal sample sizes and their powers by three well-established statistical methodologies. From the results of CAPRIE, we inferred that the minimal sample size should be 85 086 or 84 968 but its power was only 30.70%. A huge gap existed. The same was also true of CREDO and CHARISMA trials. Moreover, in CAPRIE trial, 0 was included in the 95% confidence interval and 1 was included in the 95% confidence interval for the relative risk. There were some paradoxical data in CAPRIE trial. We are led to conclude that the results in CAPRIE, CREDO, and from the subgroup analysis in CHARISMA trials were questionable. These results failed to demonstrate that clopidogrel was superior to aspirin or that clopidogrel used in combination with aspirin was better than aspirin alone. The cost-effectiveness analyses by some previous studies were not reliable.

Keywords

clopidogrel / aspirin / antiplatelet therapy / randomized blinded trial / sample size / power / confidence interval

References

[1] CAPRIE Steering Committee.. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348(9038): 1329-1339

[2] Clopidogrel approved on basis of CAPRIE study [editorial]Am J Health Syst Pharm, 1998, 55(3): 207

[3] RyanT.J., AntmanE.M., BrooksN.H., et al.. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999, 100(9): 1016-1030

[4] HammC.W., BertrandM., BraunwaldE.. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet, 2001, 358(9292): 1533-1538

[5] ManolisA.S., TzeisS., AndrikopoulosG., et al.. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents, 2005, 3(3): 203-219

[6] ErikssonP.. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the “Emperor’s New Clothes” revisited. Eur Heart J, 2004, 25(9): 720-722

[7] HowardG., McClureL.A., KrakauerJ.W., et al.. Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. Curr Opin Neurol, 2007, 20(1): 71-77

[8] Yan H, Xu YY, Zhao NQ. Medical Statistics. Beijing: People’s Medical Publishing House (Chinese), 2005, 252–254

[9] HudsonZ.. Sample size, power and effect size — what all researchers need to know. Phys Ther Sport, 2009, 10(2): 43-44

[10] LermanJ.. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth, 1996, 43(2): 184-191

[11] BiauD.J., KernéisS., PorcherR.. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin Orthop Relat Res, 2008, 466(9): 2282-2288

[12] The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345(7): 494-502

[13] MehtaS.R., YusufS., PetersR.J., et al.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281): 527-533

[14] SteinhublS.R., BergerP.B., MannJ.T.3rd, et al.. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA, 2002, 288(19): 2411-2420

[15] SabatineM.S., CannonC.P., GibsonC.M., et al.. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 2005, 352(12): 1179-1189

[16] BhattD.L., FoxK.A., HackeW., et al.. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354(16): 1706-1717

[17] DienerH.C., BogousslavskyJ., BrassL.M., et al.. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004, 364(9431): 331-337

[18] BertrandM.E., RupprechtH.J., UrbanP., et al.. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 2000, 102(6): 624-629

[19] ChenZ.M., JiangL.X., ChenY.P., et al.. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 366(9497): 1607-1621

[20] ACTIVE Writing Group of the ACTIVE InvestigatorsConnollyS., PogueJ., et al.. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, 367(9526): 1903-1912

[21] WiviottS.D., BraunwaldE., McCabeC.H., et al.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357(20): 2001-2015

[22] WangT.H., BhattD.L., FoxK.A., et al.. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J, 2007, 28(18): 2200-2207

[23] CacoubP.P., BhattD.L., StegP.G., et al.. Creager for the CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J, 2009, 30(2): 192-201

[24] HuL.P.Application of statistical triple-type theory in the design of experiments, 2006, Beijing, People’s Military Medical Press (Chinese): 223-230

[25] LemeshowS., HosmerD.W., KlarJ., et al.Adequacy of sample size in health studies, 1990, New York, NY, The World Health Organization and John Wiley and Sons: 9-14

[26] YuC.H.The statisitical analysis by EXCEL and computer experiment, 2009, Beijing, China Publishing House of Electronics Industry (Chinese): 310-319

[27] WuS.X., WANGC.X.Sample size estimation in clinical studies, 2008, Beijing, People’s Medical Publishing House (Chinese): 30-32

[28] ChowS.C., ShaoJ., WangH.S.Sample size calculations in clinical research, 2003, New York, Taylor & Francis: 92

[29] MyersR.I.. The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent), 2005, 18(4): 331-336

[30] RinglebP.A., BhattD.L., HirschA.T., et al.. Benefit of clopigogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 2004, 35(2): 528-532

[31] BhattD.L., MarsoS.P., HirschA.T., et al.. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 2002, 90(6): 625-628

[32] Sanofi-Synthélabo warned on Plavix [editorial]Scrip, 2001, 2652: 13

[33] WeintraubW.S., MahoneyE.M., LamyA., et al.. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol, 2005, 45(6): 838-845

[34] BeinartS.C., KolmP., VeledarE., et al.. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol, 2005, 46(5): 761-769

[35] MahoneyE.M., MehtaS., YuanY., et al.. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J, 2006, 151(1): 219-227

[36] WeintraubW., JönssonB., BertrandM.. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomics, 2004, 22(Suppl4): 29-41

[37] Lyseng-WilliamsonK.A., PloskerG.L.. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics, 2006, 24(7): 709-726

[38] SmithS.C.Jr, FeldmanT.E., HirshfeldJ.W.Jr, et al.. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol, 2006, 47(1): 216-235

[39] PollackC.V.Jr, AntmanE.M., HollanderJ.E., et al.. 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med, 2008, 52(4): 344-355

[40] Van de WerfF., BaxJ., BetriuA., et al.. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008, 29(23): 2909-2945

[41] KrasopoulosG., BristerS.J., BeattieW.S., et al.. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008, 336(7637): 195-198

[42] BhattD.L., HirschA.T., RinglebP.A., et al.. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J, 2000, 140(1): 67-73

[43] BégaudB., FourrierA., MooreN., et al.. The delusion of reducing sample size. Eur J Clin Pharmacol, 2003, 59(8-9): 711-712

[44] FitzmauriceG.. Sample size and power: how big is big enough?. Nutrition, 2002, 18(3): 289-290

[45] GullerU., OertliD.. Sample Size Matters: A Guide for Surgeons. World J Surg, 2005, 29(5): 601-605

[46] ColumbM.O., StevensA.. Power analysis and sample size calculations. Current Anaesthesia & Critical Care, 2008, 19(1): 12-14

[47] AraujoP., FrøylandL.. Statistical power and analytical quantification. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 847(2): 305-308

[48] LemeshowS., HosmerD.W., KlarJ., et al.Adequacy of sample size in health studies, 2001, Shanghai, Fudan University Press and Shanghai Medcial University Press: 52-54

[49] AndersonD.R., SweeneyD.J., WilliamsT.A.Statistics for Business and Economics(9th Edition), 2008, Beijing, China Machine Publishing House: 266-268

[50] McClaveJ.T., BensonP.G., SinichT.Statistics for Business and Economics, 20088th EditionBeijing, China Finacial & Economic Publishing House: 369-371

[51] YeZ.X., WangR.H., XuX.L., et al.Probability Theory & Mathematical Statistics, 2008, Beijing, Perking University Press: 274-279

[52] HuangC.L.Business Management Statistics, 2009, Beijing, Tsinghua University Press: 189-191

[53] JiaJ.P., HeX.Q., JinY.J.Statistics, 20094th EditionBeijing, China Renmin University Press: 194

[54] LiuG.J., HongQ.. Application of confidence interval(CI). Chin J Evidence-Based Med (Chinese), 2001, 1(4): 235-238

[55] ChanF.K., ChingJ.Y., HungL.C., et al.. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005, 352(3): 238-244

[56] PittB., ZannadF., RemmeW.J., et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341(10): 709-717

[57] GaspozJ.M., de MoerlooseP.. Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner?. Am J Med, 2004, 116(12): 850-852

[58] Durand-ZaleskiI., BertrandM.. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics, 2004, 22(Suppl4): 19-27

[59] BergerK., HesselF., KreuzerJ., et al.. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin, 2008, 24(1): 267-274

[60] SchleinitzM.D., HeidenreichP.A.. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med, 2005, 142(4): 251-925